Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTAX03 for Lumbosacral Facet Joint Pain
NCT06236308Phase 1Withdrawn
- Sponsor
- BioTissue
- Start
- Jul 2024
- Primary completion
- Jan 2025
- Modality
- Cell Therapies
01
Overview
Phase 1, randomised, double-blind trial of TTAX03 in Facet arthropathy (FJOA) and facet joint osteoarthritis (3 arms), sponsored by BioTissue. Primary endpoint: Physical, functional and physiological responses and unanticipated events at 12 weeks. Planned start Jul 2024; status: withdrawn.
02
Drugs
TTAX03
03
Conditions
Facet arthropathy (FJOA)facet joint osteoarthritis
Beyond the preview
Go deeper on NCT06236308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06236308.